Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:02 AM ET 8-K
Research Collaboration Oncolytics Biotech Inc ONCY

Oncolytics Biotech Research Collaboration with Coherus Oncology, Inc.

Oncolytics Biotech entered into a clinical supply agreement with Coherus Oncology to evaluate pelareorep in combination with LOQTORZI (toripalimab-tpzi) for the treatment of squamous cell anal carcinoma (SCAC). The clinical study, expected to begin in Q1 2027, will target second-line patients who have progressed on standard-of-care treatments.

Counterparty
Coherus Oncology, Inc.
7:00 AM ET 8-K
Research Collaboration Eton Pharmaceuticals, Inc. ETON

Eton Pharmaceuticals Research Collaboration with Baylor College of Medicine

Eton Pharmaceuticals has entered into a license and development agreement with Baylor College of Medicine to evaluate mecasermin (ET-900) for the treatment of infantile and epileptic spasms. The partnership includes an investigator-sponsored Phase 2 clinical study with patient dosing targeted for Q1 2027, following the submission of an Investigational New Drug application to the FDA.

Counterparty
Baylor College of Medicine
8:35 AM ET 8-K
Research Collaboration Vir Biotechnology, Inc. VIR

Vir Biotechnology Research Collaboration with Gilead Sciences, Inc. Worth $1.88B

Vir Biotechnology and Gilead Sciences have entered into a global strategic collaboration to discover and engineer three novel PRO-XTEN dual-masked T-cell engager (TCE) development candidates for solid tumors. Vir receives $90 million in upfront consideration (including a $25 million equity investment at a 30% premium) and is eligible for up to $1.785 billion in total potential milestones plus royalties.

Value
$1.88B
Counterparty
Gilead Sciences, Inc.
7:52 AM ET 8-K
Research Collaboration Regeneron Pharmaceuticals, Inc. REGN

Regeneron Pharmaceuticals Research Collaboration with Sanofi Worth $1B

Regeneron and Sanofi entered into a Sixth Amendment to their existing Antibody LCA to co-develop and co-commercialize four new long-acting antibodies targeting IL-13, IL-4, and IL-4Rα. Sanofi will pay Regeneron an upfront payment of $1.0 billion and up to $7.0 billion in potential development, regulatory, and commercial milestones, with global profits and development costs shared equally.

Value
$1B
Counterparty
Sanofi
4:06 PM ET 8-K
Research Collaboration Tempest Therapeutics, Inc. TPST

Tempest Therapeutics Research Collaboration with Factor Bioscience Inc. Worth $5M

Tempest Therapeutics entered into a Master Services Agreement and a specific work order with Factor Bioscience Inc. to develop in vivo CAR-T therapies. The agreement involves an estimated $5.0 million in annual fees and is considered a related-party transaction as Tempest's CEO, Dr. Matt Angel, is the majority owner and CEO of Factor Bioscience.

Value
$5M
Counterparty
Factor Bioscience Inc.
Term
annual
11:27 AM ET 8-K
Research Collaboration Deep Fission, Inc. FISN

Deep Fission Research Collaboration with Youngquist Brothers, LLC

Deep Fission has entered into a collaboration with Youngquist Brothers to evaluate and test drilling and borehole-construction methods for its underground nuclear reactor deployment model. The partnership leverages Youngquist's expertise in large-diameter drilling to support Deep Fission's strategy of placing small modular reactors one mile underground. The companies recently completed a successful equipment demonstration in Florida involving a 30-inch prototype reactor canister.

Counterparty
Youngquist Brothers, LLC
8:56 AM ET 8-K
Research Collaboration Beeline Holdings, Inc. BLNE

Beeline Holdings Research Collaboration with Loft 100 Studios

Beeline Holdings has partnered with Emmy Award-winning Loft 100 Studios to produce a "Bizumentary" exploring the mortgage and housing crisis. The 45-minute production will examine industry challenges and innovative lending solutions, with an expected initial distribution reaching up to 90 million viewers via BizTV and other networks.

Counterparty
Loft 100 Studios
5:06 PM ET 8-K
Research Collaboration Tempest Therapeutics, Inc. TPST

Tempest Therapeutics Research Collaboration with Heibei Senlang Biotechnology Co., Ltd.

Tempest Therapeutics entered into an exclusive collaboration and option agreement with Heibei Senlang Biotechnology to develop and commercialize an in vivo CAR-T technology platform worldwide, excluding Greater China. Tempest paid an option fee of approximately $0.447 million for a four-month window to license the technology, which includes a Phase 1 dual-targeting candidate for multiple myeloma. The deal establishes Tempest as a multi-platform in vivo CAR-T company, combining Senlang's lentiviral vector platform with Tempest's existing LNP delivery technology.

Counterparty
Heibei Senlang Biotechnology Co., Ltd.
Term
4 month option period

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.